A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

<p>Abstract</p> <p>Background</p> <p>IL-13 has been implicated in the development of airway inflammation and hyperresponsiveness. This study investigated the multiple-dose pharmacokinetics and safety profile of human anti-IL-13 antibody (CAT-354) in adults with asthma.&...

Full description

Bibliographic Details
Main Authors: Roskos Lorin, Faggioni Raffaella, Molfino Nestor A, Kane Binita, Singh Dave, Woodcock Ashley
Format: Article
Language:English
Published: BMC 2010-01-01
Series:BMC Pulmonary Medicine
Online Access:http://www.biomedcentral.com/1471-2466/10/3

Internet

http://www.biomedcentral.com/1471-2466/10/3

Similar Items